Taiwan Exosome Company Opens a New Chapter in Regenerative Medicine! Storming the Japanese Bridgehead to Lead the Global Pharmaceutical Market

(Second from left) Dr. Chen Zhen-xing, CEO of Taiwan Exosome Co., Ltd.; (First from left) Dr. Lin Jie-liang, COO and CTO; (Third from right) Supervisor and Distinguished Professor Chu Chun-chieh; (First from right) Li Wen-yu, Cell Factory Team Leader, and the R&D team.
Powered by Taiwan Exosome Co., Ltd.
2025/12/26
Following the AI industry, exosomes are expected to become the second "Silicon Shield" (National Guardian Mountain) to take the baton from AI.
In Taiwan, there is a biotech startup that possesses dual technologies in exosome development and NK cell therapy—capabilities rare globally. Starting from Taiwan's technological innovation and partnering with Japanese manufacturing, they are opening up global market channels.
Originally considered cellular metabolic waste, exosomes were deeply researched by three American and German scientists who unlocked the mechanism of information transmission between cells, leading to the 2013 Nobel Prize in Physiology or Medicine.
Since then, the global scientific community has gradually revealed the abilities of exosomes to repair tissues and activate cells, making them a hot topic in regenerative medicine and hailed as the most investment-worthy emerging industry "after AI." Currently, in addition to being widely used in medical aesthetics, the medical community holds high hopes for using them to treat major diseases.
R&D Hard Power: First Company in Taiwan Certified by the Ministry of Health and Welfare
Founded in 2021, Taiwan Exosome Co., Ltd. (TEC) has mastered core technologies for developing human, animal, and plant exosomes. Aiming at hard-to-treat diseases such as autoimmune diseases and sarcopenia, it has established a "Medical-Grade Exosome Industrial Technology Platform."
Dr. Chen Zhen-xing, CEO of Taiwan Exosome Co., Ltd., pointed out that the company is the only one domestically and one of the few internationally to simultaneously deploy three sources of exosomes—human, plant, and animal. Based on the commonality of basic elements (such as carbon) in biological cells, synchronous research and development are conducted. Consequently, the company obtained approval from the Ministry of Health and Welfare for "Allogeneic NK Cell (Natural Killer Cell)" technology (the 6th in the world and 1st in Taiwan), possessing three major manufacturing advantages: "Immune Cell Preparations, Exosome R&D, and Academic-Medical Clinical Validation."

 

Dr. Chen Zhen-xing, CEO of Taiwan Exosome Co., Ltd.
Taiwan Technology + Japanese Manufacturing: Aiming at the Global Market
Taiwan Exosome Co., Ltd. has established the nation’s first clinical-grade universal (non-matching and non-gene-modified) NK cell platform, possessing the critical capabilities necessary to advance into clinical trials.
Currently, Taiwan Exosome Co., Ltd. is invested in research related to exosomes released by NK cells, covering clinical fields such as cancer, autoimmunity, neurodegeneration, and anti-aging, demonstrating the R&D energy of innovative biomedical technology.
Compared to major pharmaceutical powers in Europe and America, the R&D strength of Taiwan Exosome Co., Ltd. is highly competitive internationally. Furthermore, Dr. Chen believes that the exosome injections currently under development are estimated to cost less than 10,000 TWD per dose. Compared to traditional cell therapies that often cost millions, the price is extremely affordable. Additionally, they can be stored at room temperature and are resistant to X-ray radiation, which facilitates global shipping and market penetration.
However, bringing Taiwanmade pharmaceuticals to the global market is far from simple. Dr. Chen explained that Taiwan’s new drug development has relatively low global visibility, which 
increases the difficulty of marketing and expanding into international markets. 
Therefore, Taiwan Exosome Company has formulated a “leveraging external strengths” market strategy: to enter Japan, a country neighboring Taiwan and serving as a key hub for the Asian market.
In July 2025, Taiwan Exosome Co., Ltd.  established "Japan Exosome Co., Ltd.," with Dr. Chen serving as Chairman. Taiwan Exosome Co., Ltd. is responsible for driving the core technology, paired with Japan's rigorous, mature, and quality-guaranteed drug manufacturing, as well as its trusted marketing channel advantages, to explore the Japanese and international markets.
"Japanese clinical data is more easily recognized by the United States and the European Union, making it the best springboard for entering the global market," said Dr. Chen. Japan Exosome has already scheduled its development timeline, with production and pre-clinical trials expected to launch in Japan in the first quarter of 2026.